4KFZ

Crystal structure of LMO2 and anti-LMO2 VH complex


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.239 
  • R-Value Observed: 0.240 

wwPDB Validation   3D Report Full Report


This is version 1.0 of the entry. See complete history


Literature

Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.

Sewell, H.Tanaka, T.Omari, K.E.Mancini, E.J.Cruz, A.Fernandez-Fuentes, N.Chambers, J.Rabbitts, T.H.

(2014) Sci Rep 4: 3643-3643

  • DOI: 10.1038/srep03643
  • Primary Citation of Related Structures:  
    4KFZ

  • PubMed Abstract: 
  • LMO2 was discovered via chromosomal translocations in T-cell leukaemia and shown normally to be essential for haematopoiesis. LMO2 is made up of two LIM only domains (thus it is a LIM-only protein) and forms a bridge in a multi-protein complex. We have studied the mechanism of formation of this complex using a single domain antibody fragment that inhibits LMO2 by sequestering it in a non-functional form ...

    LMO2 was discovered via chromosomal translocations in T-cell leukaemia and shown normally to be essential for haematopoiesis. LMO2 is made up of two LIM only domains (thus it is a LIM-only protein) and forms a bridge in a multi-protein complex. We have studied the mechanism of formation of this complex using a single domain antibody fragment that inhibits LMO2 by sequestering it in a non-functional form. The crystal structure of LMO2 with this antibody fragment has been solved revealing a conformational difference in the positioning and angle between the two LIM domains compared with its normal binding. This contortion occurs by bending at a central helical region of LMO2. This is a unique mechanism for inhibiting an intracellular protein function and the structural contusion implies a model in which newly synthesized, intrinsically disordered LMO2 binds to a partner protein nucleating further interactions and suggests approaches for therapeutic targeting of LMO2.


    Organizational Affiliation

    1] Weatherall Institute of Molecular Medicine MRC Molecular Haematology Unit University of Oxford John Radcliffe Hospital Oxford OX3 9DS, UK [2] Leeds Institute of Molecular Medicine Wellcome Trust Brenner Building St. James's University Hospital University of Leeds Leeds, LS9 7TF, UK.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
LMO-2A, B150Homo sapiensMutation(s): 0 
Gene Names: LMO2RBTN2RBTNL1RHOM2TTG2
UniProt & NIH Common Fund Data Resources
Find proteins for P25791 (Homo sapiens)
Explore P25791 
Go to UniProtKB:  P25791
PHAROS:  P25791
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP25791
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Anti-LMO2 VHC, D129Homo sapiensMutation(s): 0 
Gene Names: Anti-LMO2 VHIGHV3-23
UniProt & NIH Common Fund Data Resources
Find proteins for P01764 (Homo sapiens)
Explore P01764 
Go to UniProtKB:  P01764
PHAROS:  P01764
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP01764
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.258 
  • R-Value Work: 0.239 
  • R-Value Observed: 0.240 
  • Space Group: P 6
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 124.26α = 90
b = 124.26β = 90
c = 81.44γ = 120
Software Package:
Software NamePurpose
ADSCdata collection
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2014-01-22
    Type: Initial release